Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor

The majority of gastrointestinal stromal tumors (GIST) harbor an activating mutation in either the KIT or PDGFRA receptor tyrosine kinases. Approval of imatinib, a KIT/PDGFRA tyrosine kinase inhibitor (TKI), meaningfully improved the treatment of advanced GIST. Other TKIs subsequently gained approva...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Front Oncol
Huvudupphovsmän: Bauer, Sebastian, George, Suzanne, von Mehren, Margaret, Heinrich, Michael C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Frontiers Media S.A. 2021
Ämnen:
Oncology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8313277/
https://ncbi.nlm.nih.gov/pubmed/34322383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.672500
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk